The Daniel Bravo Andreu Private Foundation has awarded its grants for biomedical research stays at benchmark centres abroad to PhD candidate Carles Diez of Bellvitge University Hospital–Bellvitge Biomedical Research Institute (IDIBELL)
The “Elles contra ELA” solidarity campaign begins today with the aim of raising awareness about ALS and raising funds for research. This project is promoted by the research group on neurological and neurogenetic diseases of the Bellvitge Biomedical Research Institute (IDIBELL), with the support of the Catalan Foundation of ALS Miquel Valls, the sponsorship of …
The solidarity campaign “Elles contra l’ELA” kicks off Read More »
This new CRISPR-Cas9 tool can modify gene sites that were inaccessible until now, which bypasses the limited capabilities of gene editing and reinforce precision medicine.
The protein can slow down the proinflammatory activity of the immune cells and, therefore, stop their body attack.
It begins the selection of candidates to carry out a doctoral program in Regenerative Medicine between the SZBL and the IDIBELL. The program will run mainly at SZBL and will have a minimum six months stay at IDIBELL.
The analysis show that these vaccines are safe and able to generate immunity in three out of four patients with immune system defects from birth, and in almost all patients treated with immunosuppressants who were evaluated in the study.
Preliminary results show that the virus is active, reaches the primary tumor and metastases, and triggers the immune system response. In addition, at recommended doses, it has no important adverse effects.
Lack of family and social support and depressive symptoms are the main factors that impair patients’ ability to adopt healthy habits and practices.
The initiative, promoted by the Escolab program and carried out by IDIBELL, has been carried out with 4th year ESO students from the Escola Pia of Granollers.
An international consortium led by IRB Barcelona and the biotech company Merus, with the participation of IDIBELL and the Catalan Institute of Oncology, presents the preclinical data leading to the discovery of MCLA-158 and its action mechanism on cancer stem cells.
